Aqr Capital Management LLC Neurocrine Biosciences Inc Transaction History

Aqr Capital Management LLC

$71.5 Billion
Q3 2024

A detailed history of Aqr Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 1,843,281 shares of NBIX stock, worth $245 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares

1,843,281

Previous 1,223,055 50.71%

Holding current value

$245 Million

Previous $168 Million 26.04%

% of portfolio

0.3%

Previous 0.26%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $71.1 Million - $95 Million	620,226 Added 50.71%	1,843,281 $212 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $29.9 Million - $32.7 Million	228,444 Added 22.97%	1,223,055 $168 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $33.4 Million - $36.8 Million	255,759 Added 34.62%	994,611 $137 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $38.7 Million - $48.4 Million	364,890 Added 97.57%	738,852 $97.4 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $1.53 Million - $1.9 Million	16,264 Added 4.55%	373,962 $42.1 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $11.3 Million - $13.3 Million	126,624 Added 54.8%	357,698 $33.7 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $11.7 Million - $15.3 Million	124,539 Added 116.9%	231,074 $23.4 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $754,296 - $898,060	-7,068 Reduced 6.22%	106,535 $12.7 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $7.51 Million - $8.8 Million	81,596 Added 254.93%	113,603 $11.9 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $3.09 Million - $4.08 Million	-40,742 Reduced 56.0%	32,007 $3.1 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $2.01 Million - $2.63 Million	-27,772 Reduced 27.63%	72,749 $6.79 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $4.22 Million - $5.63 Million	52,958 Added 111.34%	100,521 $8.56 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $607,741 - $698,359	7,052 Added 17.41%	47,563 $4.54 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $141,299 - $161,586	-1,580 Reduced 3.75%	40,511 $3.91 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $2.69 Million - $3.67 Million	30,775 Added 271.96%	42,091 $4.09 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $3.29 Million - $4.1 Million	-37,808 Reduced 76.96%	11,316 $1.06 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $92,025 - $129,338	957 Added 1.99%	49,124 $4.72 Million
Q2 2020 Aug 17, 2020	BUY	$85.09 - $130.36 $1.2 Million - $1.84 Million	14,097 Added 41.38%	48,167 $5.88 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $698,673 - $1.06 Million	9,302 Added 37.56%	34,070 $2.95 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $1.15 Million - $1.57 Million	13,257 Added 115.17%	24,768 $2.65 Million
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $99,913 - $120,988	1,192 Added 11.55%	11,511 $1.03 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $3.71 Million - $4.68 Million	-51,329 Reduced 83.26%	10,319 $850,000
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $4.01 Million - $5.3 Million	-57,876 Reduced 48.42%	61,648 $5.43 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $3.65 Million - $6.65 Million	53,487 Added 81.0%	119,524 $8.54 Million
Q3 2018 Nov 15, 2018	BUY	$98.88 - $125.85 $3.81 Million - $4.86 Million	38,582 Added 140.53%	66,037 $8.12 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $883,419 - $1.24 Million	11,732 Added 74.62%	27,455 $2.7 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.19 Million - $1.45 Million	15,723 New	15,723 $1.3 Million

Others Institutions Holding NBIX

# of Institutions

627

Shares Held

94.2M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.7B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.

Account

Aqr Capital Management LLC Neurocrine Biosciences Inc Transaction History